Geron Corp (GERN) is a publicly traded Healthcare sector company. As of May 20, 2026, GERN trades at $1.25 with a market cap of $789.07M and a P/E ratio of -11.41. GERN moved +3.28% today. Year to date, GERN is -7.58%; over the trailing twelve months it is -12.23%. Its 52-week range spans $1.04 to $4.65. Analyst consensus is buy with an average price target of $3.25. Rallies surfaces GERN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Geron to Present First Real-World RYTELO Data at EHA 2026 Congress: Geron Corporation will present the first real-world evidence study of RYTELO (imetelstat) in lower-risk myelodysplastic syndrome patients at the EHA 2026 Congress. The retrospective analysis will provide patient-level data on RYTELO’s safety and efficacy beyond clinical trials.
| Metric | Value |
|---|---|
| Price | $1.25 |
| Market Cap | $789.07M |
| P/E Ratio | -11.41 |
| EPS | $-0.11 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.65 |
| 52-Week Low | $1.04 |
| Volume | 7.50M |
| Avg Volume | 0 |
| Revenue (TTM) | $196.12M |
| Net Income | $-67.31M |
| Gross Margin | 0.00% |
5 analysts cover GERN: 0 strong buy, 3 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.25.